No Data
No Data
UCB And Biogen Present Phase 3 Data On Dapirolizumab Pegol, Showing Significant Lupus Activity Reduction
Monday Market Slow but Steady, Trump Buying Crypto Firm | Wall Street Today
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
Needham Downgrades Biogen on Slow Growth of Alzheimer's Drug
Monday Opens to S&P 500 Climb, Dow Slides as Eyes Look Toward Nvidia | Live Stock
Biogen on Track for Lowest Close Since March 2013 -- Data Talk